Scope and Claim Analysis for US Patent 5,827,529 (Lidocaine Adhesive Gel Skin Drug-Retaining Layer)
US 5,827,529 covers a topically applied lidocaine external preparation built around a specific architecture: a support carrying a skin-adhesive, drug-retaining gel layer in which lidocaine is dissolved uniformly in a gel base defined by (i) a water-soluble, high molecular weight polymer “consisting essentially of” a named class, (ii) a mid-to-high water fraction, and (iii) a defined range of water-retaining polyols/glycols. Dependent claims further lock in release control and pH, water range, and optional absorbing-agent/surfactant selections. The estate is structurally narrow but can still read broadly on “lidocaine-in-adhesive-gel” patches if the gel chemistry falls within the stated compositional bands and the drug layer is adhesive and drug-retaining.
What does US Patent 5,827,529 claim for lidocaine external skin preparations?
Core claim scope (Claim 1): an external skin preparation comprising:
- A support
- A drug-retaining layer on the support
- Drug-retaining layer = adhesive gel base
- Adhesive gel base composition
- Lidocaine amount: 1 to 10% by weight
- High molecular weight, water-soluble substance: 0.5 to 50% by weight, selected from a defined list
- Water: 30 to 70% by weight
- Water-retaining agent: 1 to 70% by weight, selected from a defined list
- Lidocaine dissolved in the base to form a uniform base material
Claim 1 is not limited to a specific dosage form language (patch, film, plaster), but the inclusion of a “support” and “drug-retaining layer placed on a support” maps most directly to transdermal or topical skin patches with backing materials and adhesive drug reservoirs.
Key structural requirements that drive literal infringement risk
- Must have an adhesive gel base that is also explicitly a drug-retaining layer on a support.
- Lidocaine must be dissolved in the base (uniform base material). This is less compatible with reservoir systems where lidocaine is dispersed as separate phases.
- All compositional components must fall inside the stated ranges and lists.
- The polymer component is constrained by “consisting essentially of” which allows some non-listed components, but limits tolerance for additional polymers that would materially affect the base composition from the viewpoint of the claim’s “essential” characteristics.
Essential claim math issue (how to interpret component ranges)
The claim sets independent ranges for four weight fractions:
- Polymer: 0.5–50%
- Lidocaine: 1–10%
- Water: 30–70%
- Water-retaining agent: 1–70%
That framing permits formulations where the sum of these ingredients may exceed 100% on paper if treated as independent constraints, but in practice examiners and courts construe composition claims as requiring a feasible total formulation. Practically, this claim reads on gels where water and the water-retaining agent are substantial, with polymer as the gel-forming matrix and lidocaine dissolved within.
How does the “consisting essentially of” polymer clause narrow or broaden coverage?
Claim 1: the adhesive gel base includes a polymer component stated as:
“said base consisting essentially of 0.5 to 50% by weight of a water-soluble high molecular weight substance selected from the group consisting of …”
Legal effect in plain terms: “consisting essentially of” typically allows inclusion of other ingredients that do not materially change the basic and novel characteristics of the claimed composition. Here, the basic characteristics are:
- a water-soluble high molecular weight gel former from the enumerated class,
- a high water content,
- and a high-capacity water-retaining polyol/glycol phase.
Practical scope consequence:
- Replacing the enumerated polymer class with an unlisted gel polymer (for example, a different acrylic polymer not in the list, a different cellulose derivative not in the list, or a different natural polysaccharide) risks non-literal infringement because the polymer clause is framed as a “selected from the group consisting of” list.
- Adding minor excipients outside the polymer list (buffers, salts, small surfactants) may still fit under “consisting essentially of” depending on whether they materially alter the base’s essential character. Claim 4 then expressly contemplates additional absorbing agents and a surfactant, showing that non-listed functional excipients are within the concept of the base.
Which polymers and water-retaining agents are explicitly covered by Claim 1?
Water-soluble high molecular weight substances (polymer gel formers)
Covered list (must select from this group; amount 0.5–50% by weight):
- gelatin
- starch
- agar
- mannan
- alginic acid
- polyacrylic acid
- a salt of polyacrylic acid
- dextrin
- methylcellulose
- methylcellulose sodium
- carboxymethylcellulose
- carboxymethylcellulose sodium
- polyvinyl alcohol
- polyvinyl pyrrolidone
- copolymer of methyl vinyl ether and maleic anhydride
- gum arabic
- tragacanth
- karaya gum
- locust bean gum
Scope note: This list is broad across natural polymers and cellulose derivatives, but it is also finite. Unlisted gel-formers are a carve-out.
Water-retaining agents (polyols/glycols)
Covered list (amount 1–70% by weight):
- ethylene glycol
- diethylene glycol
- polyethylene glycol
- glycerin
- sorbitol
- martitol
- propylene glycol
- 1,3-butylene glycol
Scope note: These are classic humectants/plasticizers for adhesive gels. Coverage is wide in the sense that multiple common transdermal gel humectants are included.
What does the claim require about lidocaine form and distribution?
Claim 1 requires:
- Lidocaine is dissolved in the base to produce a uniform base material.
Claim interpretation impact:
- A formulation where lidocaine is present as a microcrystalline solid or as a separate reservoir layer not dissolved into the adhesive gel phase is more likely to fall outside literal scope.
- A formulation where lidocaine is truly molecularly dissolved or uniformly solubilized into the gel base supports literal alignment.
How do dependent claims change scope: release control, pH, and water content?
Claim 2: pH and release control
“adhesive gel base is capable of controlling the release of drug and has a pH value of 5 to 9.”
Two separate limitations:
- a functional capability: “capable of controlling release”
- a compositional/measurement limitation: pH 5–9
Practical effect: even if a gel matches Claim 1 composition, it still needs to have pH in range and exhibit release-control behavior consistent with the claimed base.
Claim 3: water content
“water content… is 20 to 50% by weight.”
Scope relationship to Claim 1: Claim 1 already recites water 30–70%. Claim 3 narrows to 20–50, creating an overlap only in 30–50%.
Claim 6: broader water range than Claim 3
Claim 6: “water is present in an amount of 34.55% to 70% by weight.”
Scope: overlaps substantially with Claim 1, but pins a narrower lower bound than Claim 1:
- Claim 1 allows water 30–70
- Claim 6 allows water 34.55–70
This gives Claim 6 additional cover for formulations with water toward the upper range.
What additional composition elements are claimed in Claim 4 (absorbing agent and surfactant)?
Claim 4 depends on Claim 1 and adds:
- the base consists essentially of the polymer/water/humectant system and further includes:
- an absorbing agent and a surfactant
- lidocaine is dissolved to form uniform material
Claim 5 specifies the absorbing agent and surfactant lists
Absorbing agent list (select one or more; claim says “selected from”):
- salicylic acid
- hyaluronic acid
- oleic acid
- N,N-diethyl-m-toluamide (DEET)
- n-butyl stearate
- benzyl alcohol
- isopropyl myristate
- isopropyl palmitate
- polypropylene glycol
- crotamiton
- diethyl sebacate
- N-methylpyrrolidone
- N-ethylpyrrolidone
- lauryl alcohol
Surfactant list (select one or more):
- polyoxyethylene sorbitan monooleate
- polyoxyethylene sorbitan monostearate
- sorbitan monooleate
- sorbitan monopalmitate
Claim 4/5 effect on scope:
- Claim 1 already covers a base with humectant, water, polymer, lidocaine, and adhesive gel architecture.
- Claims 4 and 5 broaden practical formulation space by explicitly permitting two functional excipient categories, but still constrain them to enumerated lists.
- Any lidocaine gel patch that uses a different skin absorption enhancer or a different surfactant system not in the listed groups likely avoids Claims 4/5 while still potentially infringing Claim 1 if the rest is within scope.
How strong is the claim set based on structural narrowness vs functional breadth?
Strength drivers
- The claims contain high-precision composition constraints (exact ranges and enumerated polymer and humectant lists). That precision tends to reduce prior-art collisions in litigation because fewer formulations match all element constraints simultaneously.
- The inclusion of support + adhesive drug-retaining layer is consistent with many patch architectures, so the claim can cover a broad set of commercial product designs as long as they match the gel chemistry.
Vulnerability drivers
- Because key lists are enumerated and bounded, a competitor can design around by:
- substituting a polymer outside the enumerated group,
- adjusting humectant/water contents outside the claimed bands,
- using different enhancer/surfactant pairs to avoid dependent claims (while still needing to address Claim 1 if they want to avoid everything).
- The “uniform base material” and “lidocaine dissolved” language can be used to argue non-literal infringement where lidocaine is not in the dissolved phase.
What is the practical infringement map across the claims?
Claim-by-claim infringement likelihood
- Claim 1 (highest baseline risk): covers most “lidocaine adhesive gel” patch concepts where polymer is one of the enumerated gel formers, water and glycol/humectant are within ranges, and lidocaine is dissolved.
- Claim 2 (additional risk): only if pH is 5–9 and the formulation is engineered to control release.
- Claim 3 (narrower): only if water is 20–50% (overlapping with Claim 1 at 30–50%).
- Claim 4/5 (additional risk): only if specific absorbing agent(s) and surfactant(s) from the listed groups are used.
- Claim 6 (additional risk): if water is 34.55–70%.
What patent landscape issues matter beyond the text of the claims?
The question requests analysis of scope and claims for US 5,827,529. A complete “landscape” requires bibliographic and legal-status facts such as:
- priority date and filing history,
- prosecution history,
- specification examples,
- terminal disclaimer status,
- prosecution of continuations/divisionals,
- whether the patent was reexamined or amended,
- and current legal status (expired, active, or lapsed).
Those elements are not provided in the prompt, so only claim-scope construction can be analyzed reliably from the claims text alone.
Key Takeaways
- US 5,827,529 Claim 1 covers a lidocaine (1–10% w/w) adhesive gel drug-retaining layer on a support where lidocaine is dissolved in a base made from:
- 0.5–50% w/w of a listed water-soluble high molecular weight polymer,
- 30–70% w/w water,
- 1–70% w/w of a listed water-retaining agent (glycols/polyols).
- “Consisting essentially of” on the polymer base constrains the gel-former to the enumerated polymer list while leaving room for minor, non-material excipients.
- Dependent claims narrow with:
- pH 5–9 and release control (Claim 2),
- water content bands (Claims 3 and 6),
- optional but constrained addition of listed absorbing agents and listed surfactants (Claims 4–5).
- Design-around strategies that target the polymer list, lidocaine dissolution requirement, or water/humectant bands offer the highest probability of avoiding Claim 1. Changes only to enhancers/surfactants mainly avoid Claims 4–5 while leaving Claim 1 risk.
FAQs
1) Does US 5,827,529 cover lidocaine patches or only gels?
It covers an external preparation with a support and an adhesive gel drug-retaining layer. That language maps to patch-like delivery systems that include a backing/support and a gel reservoir.
2) Are absorption enhancers mandatory to infringe US 5,827,529?
No. Absorbing agents and surfactants are required only in dependent claims (Claims 4–5). Claim 1 stands without them.
3) What lidocaine loading range is required by the independent claim?
Claim 1 requires 1 to 10% by weight lidocaine.
4) Can the gel use any polymer as the gel former?
No. Claim 1 limits the high molecular weight, water-soluble substance to the enumerated list and sets it at 0.5–50% by weight.
5) What pH range triggers dependent Claim 2?
Claim 2 requires the adhesive gel base to have pH 5 to 9 and to be capable of controlling release.
References
No external sources were cited because the request provided only the claim text for US 5,827,529 and did not include bibliographic, prosecution, legal-status, or specification information.
